Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies

Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates decision making during drug discovery, and increases the probability of success for early clinical trials. Standard strategies employed for predicting the pharmacokinetics of small-molecule drugs (e.g., allo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmacokinetics and pharmacodynamics 2016-08, Vol.43 (4), p.427-446
Hauptverfasser: Glassman, Patrick M., Balthasar, Joseph P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 446
container_issue 4
container_start_page 427
container_title Journal of pharmacokinetics and pharmacodynamics
container_volume 43
creator Glassman, Patrick M.
Balthasar, Joseph P.
description Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates decision making during drug discovery, and increases the probability of success for early clinical trials. Standard strategies employed for predicting the pharmacokinetics of small-molecule drugs (e.g., allometric scaling) are often not useful for predicting the disposition monoclonal antibodies (mAbs), as mAbs frequently demonstrate species-specific non-linear pharmacokinetics that is related to mAb-target binding (i.e., target-mediated drug disposition, TMDD). The saturable kinetics of TMDD are known to be influenced by a variety of factors, including the sites of target expression (which determines the accessibility of target to mAb), the extent of target expression, the rate of target turnover, and the fate of mAb-target complexes. In most cases, quantitative information on the determinants of TMDD is not available during early phases of drug discovery, and this has complicated attempts to employ mechanistic mathematical models to predict the clinical pharmacokinetics of mAbs. In this report, we introduce a simple strategy, employing physiologically-based modeling, to predict mAb disposition in humans. The approach employs estimates of inter-antibody variability in rate processes of extravasation in tissues and fluid-phase endocytosis, estimates for target concentrations in tissues derived through use of categorical immunohistochemical scores, and in vitro measures of the turnover of target and target-mAb complexes. Monte Carlo simulations were performed for four mAbs (cetuximab, figitumumab, dalotuzumab, trastuzumab) directed against three targets (epidermal growth factor receptor, insulin-like growth factor receptor 1, human epidermal growth factor receptor 2). The proposed modeling strategy was able to predict well the pharmacokinetics of cetuximab, dalotuzumab, and trastuzumab at a range of doses, but trended towards underprediction of figitumumab concentrations, particularly at high doses. The general agreement between model predictions and experimental observations suggests that PBPK modeling may be useful for the a priori prediction of the clinical pharmacokinetics of mAb therapeutics.
doi_str_mv 10.1007/s10928-016-9482-0
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811901108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1806441982</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-44bdff1cbabf7b9f3daa0868b9ac53cb8c048cac036214e14dbca73c0db8faeb3</originalsourceid><addsrcrecordid>eNqNkc1q3DAURkVpaX7aB-gmGLLpRum9tsaSlyGkSSDQLlroTkhX8oxS23Ikz2LevhomKSUQ6EJI6J7zCfEx9gnhAgHkl4zQ1YoDtrwTqubwhh3jSjZcSSHe7s-t5GX9OmInOT9AAVc1vGdHtWykbBCP2fx9s8shDnEdyAzDjluTvavmjUmjofg7TH4JVI3R-SFM62qJ1Zy8C7RUy8ZXVC734kshV7Ev0hRpiFMZm2kJNrrg8wf2rjdD9h-f9lP28-v1j6tbfv_t5u7q8p6TkLhwIazreyRrbC9t1zfOGFCtsp2hVUNWEQhFhqBpaxQehbNkZEPgrOqNt80p-3zInVN83Pq86DFk8sNgJh-3WaNC7AAR1H-g0AqBnaoLev4CfYjbVH74HLiqpSgUHihKMefkez2nMJq00wh635w-NKdLIXrfnIbinD0lb-3o3V_juaoC1Acgl9G09umfp19N_QPwO6bZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811905274</pqid></control><display><type>article</type><title>Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>Glassman, Patrick M. ; Balthasar, Joseph P.</creator><creatorcontrib>Glassman, Patrick M. ; Balthasar, Joseph P.</creatorcontrib><description>Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates decision making during drug discovery, and increases the probability of success for early clinical trials. Standard strategies employed for predicting the pharmacokinetics of small-molecule drugs (e.g., allometric scaling) are often not useful for predicting the disposition monoclonal antibodies (mAbs), as mAbs frequently demonstrate species-specific non-linear pharmacokinetics that is related to mAb-target binding (i.e., target-mediated drug disposition, TMDD). The saturable kinetics of TMDD are known to be influenced by a variety of factors, including the sites of target expression (which determines the accessibility of target to mAb), the extent of target expression, the rate of target turnover, and the fate of mAb-target complexes. In most cases, quantitative information on the determinants of TMDD is not available during early phases of drug discovery, and this has complicated attempts to employ mechanistic mathematical models to predict the clinical pharmacokinetics of mAbs. In this report, we introduce a simple strategy, employing physiologically-based modeling, to predict mAb disposition in humans. The approach employs estimates of inter-antibody variability in rate processes of extravasation in tissues and fluid-phase endocytosis, estimates for target concentrations in tissues derived through use of categorical immunohistochemical scores, and in vitro measures of the turnover of target and target-mAb complexes. Monte Carlo simulations were performed for four mAbs (cetuximab, figitumumab, dalotuzumab, trastuzumab) directed against three targets (epidermal growth factor receptor, insulin-like growth factor receptor 1, human epidermal growth factor receptor 2). The proposed modeling strategy was able to predict well the pharmacokinetics of cetuximab, dalotuzumab, and trastuzumab at a range of doses, but trended towards underprediction of figitumumab concentrations, particularly at high doses. The general agreement between model predictions and experimental observations suggests that PBPK modeling may be useful for the a priori prediction of the clinical pharmacokinetics of mAb therapeutics.</description><identifier>ISSN: 1567-567X</identifier><identifier>EISSN: 1573-8744</identifier><identifier>DOI: 10.1007/s10928-016-9482-0</identifier><identifier>PMID: 27377311</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antibodies, Monoclonal - administration &amp; dosage ; Antibodies, Monoclonal - pharmacokinetics ; Biochemistry ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Computer Simulation ; Endocytosis - physiology ; Humans ; Models, Biological ; Monte Carlo Method ; Organ Specificity - physiology ; Original Paper ; Pharmacology, Clinical ; Pharmacology/Toxicology ; Pharmacy ; Physiological Phenomena ; Pinocytosis - physiology ; Tissue Distribution - physiology ; Veterinary Medicine/Veterinary Science</subject><ispartof>Journal of pharmacokinetics and pharmacodynamics, 2016-08, Vol.43 (4), p.427-446</ispartof><rights>Springer Science+Business Media New York 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-44bdff1cbabf7b9f3daa0868b9ac53cb8c048cac036214e14dbca73c0db8faeb3</citedby><cites>FETCH-LOGICAL-c471t-44bdff1cbabf7b9f3daa0868b9ac53cb8c048cac036214e14dbca73c0db8faeb3</cites><orcidid>0000-0001-6340-9370</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10928-016-9482-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10928-016-9482-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27377311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glassman, Patrick M.</creatorcontrib><creatorcontrib>Balthasar, Joseph P.</creatorcontrib><title>Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies</title><title>Journal of pharmacokinetics and pharmacodynamics</title><addtitle>J Pharmacokinet Pharmacodyn</addtitle><addtitle>J Pharmacokinet Pharmacodyn</addtitle><description>Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates decision making during drug discovery, and increases the probability of success for early clinical trials. Standard strategies employed for predicting the pharmacokinetics of small-molecule drugs (e.g., allometric scaling) are often not useful for predicting the disposition monoclonal antibodies (mAbs), as mAbs frequently demonstrate species-specific non-linear pharmacokinetics that is related to mAb-target binding (i.e., target-mediated drug disposition, TMDD). The saturable kinetics of TMDD are known to be influenced by a variety of factors, including the sites of target expression (which determines the accessibility of target to mAb), the extent of target expression, the rate of target turnover, and the fate of mAb-target complexes. In most cases, quantitative information on the determinants of TMDD is not available during early phases of drug discovery, and this has complicated attempts to employ mechanistic mathematical models to predict the clinical pharmacokinetics of mAbs. In this report, we introduce a simple strategy, employing physiologically-based modeling, to predict mAb disposition in humans. The approach employs estimates of inter-antibody variability in rate processes of extravasation in tissues and fluid-phase endocytosis, estimates for target concentrations in tissues derived through use of categorical immunohistochemical scores, and in vitro measures of the turnover of target and target-mAb complexes. Monte Carlo simulations were performed for four mAbs (cetuximab, figitumumab, dalotuzumab, trastuzumab) directed against three targets (epidermal growth factor receptor, insulin-like growth factor receptor 1, human epidermal growth factor receptor 2). The proposed modeling strategy was able to predict well the pharmacokinetics of cetuximab, dalotuzumab, and trastuzumab at a range of doses, but trended towards underprediction of figitumumab concentrations, particularly at high doses. The general agreement between model predictions and experimental observations suggests that PBPK modeling may be useful for the a priori prediction of the clinical pharmacokinetics of mAb therapeutics.</description><subject>Antibodies, Monoclonal - administration &amp; dosage</subject><subject>Antibodies, Monoclonal - pharmacokinetics</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Biomedicine</subject><subject>Computer Simulation</subject><subject>Endocytosis - physiology</subject><subject>Humans</subject><subject>Models, Biological</subject><subject>Monte Carlo Method</subject><subject>Organ Specificity - physiology</subject><subject>Original Paper</subject><subject>Pharmacology, Clinical</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Physiological Phenomena</subject><subject>Pinocytosis - physiology</subject><subject>Tissue Distribution - physiology</subject><subject>Veterinary Medicine/Veterinary Science</subject><issn>1567-567X</issn><issn>1573-8744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkc1q3DAURkVpaX7aB-gmGLLpRum9tsaSlyGkSSDQLlroTkhX8oxS23Ikz2LevhomKSUQ6EJI6J7zCfEx9gnhAgHkl4zQ1YoDtrwTqubwhh3jSjZcSSHe7s-t5GX9OmInOT9AAVc1vGdHtWykbBCP2fx9s8shDnEdyAzDjluTvavmjUmjofg7TH4JVI3R-SFM62qJ1Zy8C7RUy8ZXVC734kshV7Ev0hRpiFMZm2kJNrrg8wf2rjdD9h-f9lP28-v1j6tbfv_t5u7q8p6TkLhwIazreyRrbC9t1zfOGFCtsp2hVUNWEQhFhqBpaxQehbNkZEPgrOqNt80p-3zInVN83Pq86DFk8sNgJh-3WaNC7AAR1H-g0AqBnaoLev4CfYjbVH74HLiqpSgUHihKMefkez2nMJq00wh635w-NKdLIXrfnIbinD0lb-3o3V_juaoC1Acgl9G09umfp19N_QPwO6bZ</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Glassman, Patrick M.</creator><creator>Balthasar, Joseph P.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0001-6340-9370</orcidid></search><sort><creationdate>20160801</creationdate><title>Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies</title><author>Glassman, Patrick M. ; Balthasar, Joseph P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-44bdff1cbabf7b9f3daa0868b9ac53cb8c048cac036214e14dbca73c0db8faeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antibodies, Monoclonal - administration &amp; dosage</topic><topic>Antibodies, Monoclonal - pharmacokinetics</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Biomedicine</topic><topic>Computer Simulation</topic><topic>Endocytosis - physiology</topic><topic>Humans</topic><topic>Models, Biological</topic><topic>Monte Carlo Method</topic><topic>Organ Specificity - physiology</topic><topic>Original Paper</topic><topic>Pharmacology, Clinical</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Physiological Phenomena</topic><topic>Pinocytosis - physiology</topic><topic>Tissue Distribution - physiology</topic><topic>Veterinary Medicine/Veterinary Science</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glassman, Patrick M.</creatorcontrib><creatorcontrib>Balthasar, Joseph P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glassman, Patrick M.</au><au>Balthasar, Joseph P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies</atitle><jtitle>Journal of pharmacokinetics and pharmacodynamics</jtitle><stitle>J Pharmacokinet Pharmacodyn</stitle><addtitle>J Pharmacokinet Pharmacodyn</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>43</volume><issue>4</issue><spage>427</spage><epage>446</epage><pages>427-446</pages><issn>1567-567X</issn><eissn>1573-8744</eissn><abstract>Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates decision making during drug discovery, and increases the probability of success for early clinical trials. Standard strategies employed for predicting the pharmacokinetics of small-molecule drugs (e.g., allometric scaling) are often not useful for predicting the disposition monoclonal antibodies (mAbs), as mAbs frequently demonstrate species-specific non-linear pharmacokinetics that is related to mAb-target binding (i.e., target-mediated drug disposition, TMDD). The saturable kinetics of TMDD are known to be influenced by a variety of factors, including the sites of target expression (which determines the accessibility of target to mAb), the extent of target expression, the rate of target turnover, and the fate of mAb-target complexes. In most cases, quantitative information on the determinants of TMDD is not available during early phases of drug discovery, and this has complicated attempts to employ mechanistic mathematical models to predict the clinical pharmacokinetics of mAbs. In this report, we introduce a simple strategy, employing physiologically-based modeling, to predict mAb disposition in humans. The approach employs estimates of inter-antibody variability in rate processes of extravasation in tissues and fluid-phase endocytosis, estimates for target concentrations in tissues derived through use of categorical immunohistochemical scores, and in vitro measures of the turnover of target and target-mAb complexes. Monte Carlo simulations were performed for four mAbs (cetuximab, figitumumab, dalotuzumab, trastuzumab) directed against three targets (epidermal growth factor receptor, insulin-like growth factor receptor 1, human epidermal growth factor receptor 2). The proposed modeling strategy was able to predict well the pharmacokinetics of cetuximab, dalotuzumab, and trastuzumab at a range of doses, but trended towards underprediction of figitumumab concentrations, particularly at high doses. The general agreement between model predictions and experimental observations suggests that PBPK modeling may be useful for the a priori prediction of the clinical pharmacokinetics of mAb therapeutics.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>27377311</pmid><doi>10.1007/s10928-016-9482-0</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0001-6340-9370</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1567-567X
ispartof Journal of pharmacokinetics and pharmacodynamics, 2016-08, Vol.43 (4), p.427-446
issn 1567-567X
1573-8744
language eng
recordid cdi_proquest_miscellaneous_1811901108
source MEDLINE; Springer Online Journals
subjects Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - pharmacokinetics
Biochemistry
Biomedical and Life Sciences
Biomedical Engineering and Bioengineering
Biomedicine
Computer Simulation
Endocytosis - physiology
Humans
Models, Biological
Monte Carlo Method
Organ Specificity - physiology
Original Paper
Pharmacology, Clinical
Pharmacology/Toxicology
Pharmacy
Physiological Phenomena
Pinocytosis - physiology
Tissue Distribution - physiology
Veterinary Medicine/Veterinary Science
title Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A37%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physiologically-based%20pharmacokinetic%20modeling%20to%20predict%20the%20clinical%20pharmacokinetics%20of%20monoclonal%20antibodies&rft.jtitle=Journal%20of%20pharmacokinetics%20and%20pharmacodynamics&rft.au=Glassman,%20Patrick%20M.&rft.date=2016-08-01&rft.volume=43&rft.issue=4&rft.spage=427&rft.epage=446&rft.pages=427-446&rft.issn=1567-567X&rft.eissn=1573-8744&rft_id=info:doi/10.1007/s10928-016-9482-0&rft_dat=%3Cproquest_cross%3E1806441982%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811905274&rft_id=info:pmid/27377311&rfr_iscdi=true